ImmunoGen, Inc. Announces Development of Trastuzumab Emtansine for Early Stage HER2-Positive Breast Cancer
Among the study findings reported are:
• Treatment with trastuzumab emtansine significantly improved progression-free survival (PFS) compared to treatment with lapatinib plus capecitabine, as assessed by an independent review committee. Median PFS was 9.6 months compared to 6.4 months, respectively. The hazard ratio (HR) was 0.65 (p<0.0001), meaning that trastuzumab emtansine reduced the risk of cancer progression or death by 35% relative to treatment with lapatinib plus capecitabine. PFS is a co-primary endpoint of EMILIA.
• Overall survival (OS) is also a co-primary endpoint of EMILIA, and the OS data are not mature at this time. A sufficient number of events have occurred to establish median OS for the lapatinib plus capecitabine treatment group (23.3 months) but not yet for the trastuzumab emtansine treatment group, and thus longer follow up is required.
• For trastuzumab emtansine-treated patients, estimated one-year survival was 84.7% and estimated two-year survival was 65.4%. For the patients receiving lapatinib plus capecitabine, estimated one-year and two-year survival rates were 77.0 % and 47.5%, respectively.
• Fewer trastuzumab emtansine-treated patients experienced Grade 3 or higher (severe) adverse events (AEs) than those treated with lapatinib plus capecitabine (40.8% vs. 57%, respectively). The most common of these Grade 3 or higher AEs with trastuzumab emtansine were low platelet count (12.9%), increased enzymes released by the liver/other organs (4.3% and 2.9%, depending on enzyme type), and anemia (2.7%), findings consistent with previous studies. The most common Grade 3 or higher AEs with lapatinib plus capecitabine were diarrhea (20.7%), hand-foot syndrome (16.4%), vomiting (4.5%), and neutropenia (4.3%).
The EMILIA data have been selected for presentation in a plenary session of the American Society of Clinical Oncology (ASCO) annual meeting this afternoon (Abstract #LBA1) and were also featured in the official ASCO press program. “These results show that trastuzumab emtansine can make a notable difference for patients and their families,” commented Daniel Junius, President and CEO. “We developed our TAP technology to achieve markedly better anticancer therapies and believe these data validate our approach. We look forward to Roche applying for marketing approval of trastuzumab emtansine.”
In addition to EMILIA, trastuzumab emtansine is in Phase III testing for treatment of HER2-positive metastatic breast cancer in the MARIANNE and TH3RESA trials.
About ImmunoGen’s Targeted Antibody Payload (TAP) Technology
ImmunoGen developed its TAP technology to achieve more effective, better tolerated anticancer drugs. A TAP compound consists of a manufactured antibody that binds specifically to a target found on tumor cells with one of the Company’s highly potent cancer cell-killing agents attached as a payload using one of ImmunoGen’s engineered linkers. The antibody serves to target the payload specifically to the cancer cells and the payload serves to kill the cancer cells. In some compounds, the antibody component also has meaningful anticancer activity.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer cell-killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development with a wealth of clinical data reported. ImmunoGen’s collaborative partners include Amgen, Bayer HealthCare, Biotest, Lilly, Novartis, Roche and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.
This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including trastuzumab emtansine, including risks related to clinical studies and regulatory submissions, their timings and results. A review of these risks can be found in ImmunoGen’s Annual Report on Form 10-K for the fiscal year ended June 30, 2011 and other reports filed with the Securities and Exchange Commission.
Tykerb® is a registered trademark of GlaxoSmithKline plc. Xeloda® is a registered trademark of Roche. Herceptin® is a registered trademark of Genentech, a member of the Roche Group.